Dimension Therapeutics Priced, Nasdaq: DMTX

Developing novel, liver-directed gene therapies for rare genetic disorders.

Industry: Health Care

Latest Trade: $1.50 0.00 (0.0%)

First Day Return: -16.9%

Return from IPO: -88.5%

Industry: Health Care

We are a leading gene therapy platform company focused on discovering and developing new therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. Our initial programs address hemophilia B, hemophilia A, OTC deficiency and GSDIa. We retain the global rights to all of our programs, with the exception of our hemophilia A program, which is partnered with Bayer. We have developed a robust scientific platform that brings together deep expertise in rare genetic diseases, liver biology, AAV gene therapy and vector manufacturing. We believe that by leveraging the expertise created by our platform we will be able to accelerate the research and development of our pipeline of programs while continuing to discover and develop the next generation of products in this field. We believe that our manufacturing processes, methods and expertise will ultimately give us the most comprehensive manufacturing platform developed to date for AAV-based gene therapy product candidates.
more less
IPO News for Dimension Therapeutics
more
IPO Data
IPO File Date 09/14/2015
Offer Price $13.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.5
Deal Size ($mm) $72
IPO Data
IPO Date 10/21/2015
Offer Price $13.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.5
Deal Size ($mm) $72
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2013
Employees 49
Website www.dimensiontx.com